Last reviewed · How we verify
Grippol Plus
Grippol Plus is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against seasonal influenza virus strains.
Grippol Plus is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against seasonal influenza virus strains. Used for Seasonal influenza prevention in adults and children.
At a glance
| Generic name | Grippol Plus |
|---|---|
| Sponsor | NPO Petrovax |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated (killed) influenza virus antigens, typically from three or four circulating strains, which trigger both humoral and cellular immune responses. This allows the body to recognize and mount a rapid defense against natural influenza infection. Grippol Plus is a Russian-produced seasonal flu vaccine designed to provide protection against seasonal influenza.
Approved indications
- Seasonal influenza prevention in adults and children
Common side effects
- Injection site reactions (pain, redness, swelling)
- Fever
- Myalgia
- Headache
Key clinical trials
- Safety, Reactogenicity, Immunogenicity, Efficacy of Influenza Vaccines Grippol® Quadri and Grippol® Plus in Volunteers (PHASE2, PHASE3)
- A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Grippol Plus CI brief — competitive landscape report
- Grippol Plus updates RSS · CI watch RSS
- NPO Petrovax portfolio CI